D
Deborah Grady
Researcher at University of California, San Francisco
Publications - 276
Citations - 44747
Deborah Grady is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Estrogen & Hormone therapy. The author has an hindex of 88, co-authored 269 publications receiving 43348 citations. Previous affiliations of Deborah Grady include Veterans Health Administration & San Francisco General Hospital.
Papers
More filters
Journal ArticleDOI
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Journal ArticleDOI
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Deborah Grady,Susan M. Rubin,Diana B. Petitti,Cary Fox,Dennis M. Black,Bruce Ettinger,Virginia L. Ernster,Steven R. Cummings +7 more
TL;DR: To critically review the risks and benefits of hormone therapy for asymptomatic postmenopausal women who are considering long-term hormone therapy to prevent disease or to prolong life-long hormone therapy is critically reviewed.
Journal ArticleDOI
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)
Stephen B. Hulley,Curt D. Furberg,Elizabeth Barrett-Connor,Jane A. Cauley,Deborah Grady,William L. Haskell,Robert H. Knopp,Maureen Lowery,Suzanne Satterfield,Helmut G. Schrott,Eric Vittinghoff,Donald B. Hunninghake +11 more
TL;DR: Lower rates of CHD events among women in the hormone group in the final years of HERS did not persist during additional years of follow-up, and hormone therapy did not reduce risk of cardiovascular events in women with CHD.
Journal ArticleDOI
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
Steven R. Cummings,Stephen Eckert,Kathryn A. Krueger,Deborah Grady,Trevor J. Powles,Jane A. Cauley,Larry Norton,Thomas Nickelsen,Nina H. Bjarnason,Monica Morrow,Marc E. Lippman,Dennis M. Black,Joan Ellen Glusman,Alberto Costa,V. Craig Jordan +14 more
TL;DR: The Multiple Outcomes of Raloxifene Evaluation (MORE) as discussed by the authors was a multicenter, randomized, double-blind trial, in which women taking raloxion hydrochloride or placebo were followed up for a median of 40 months at 180 clinical centers composed of community settings and medical practices in 25 countries, mainly in the United States and Europe.
Journal ArticleDOI
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease, and the treatment did increase the rate of thromboembolic events and gallbladder disease.